Current or past participation in a study of an investigational agent or using an investigational device within four weeks of registration for protocol therapy
Use of an investigational agent or an investigational device within 21 days before administration of first dose of study drug(s).
Prior participation in an investigational study (drug, procedure or device) within 21 days of study day 1.
Use of an investigational agent or an investigational device within 28 days before administration of first dose of study drug(s).
Participation in a clinical trial in which the patient received an investigational drug or device must be discontinued at enrollment.
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks prior to study registration
Current or planned participation in a study of an investigational agent or using an investigational device
Are currently enrolled in, or have discontinued within 30 days of screening, from a clinical trial involving an investigational product or non-approved use of a drug or device.
Participation in a study of an investigational agent or device within 4 weeks of Day
Treatment within 30 days prior to randomization with another investigational device or drug study (ies).
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 2 weeks of trial entry (signing of the informed consent form)
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)
Current or planned participation in a study of another investigational agent or using an investigational device.
Planned participation in another study of an investigational agent or investigational device or planned use of any other agent or therapeutic device intended for therapy of glioma
Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 14 days or 5 half lives before enrollment or is currently enrolled in the treatment stage of an investigational study
Participation in a clinical trial in which the patient received an investigational drug or device or the off-label use of a drug or device within 3 months of enrollment
Current or planned participation in a study of an investigational agent or using an investigational device
Current enrollment in an investigational drug or device study or participation in such a study within 30 days of cycle 1 day 1.
Currently receiving treatment in another investigational device or drug study.
Currently receiving treatment with another investigational device or drug study, or < 28 days since ending treatment with another investigational device or drug study(s); other investigational procedures while participating in this study are excluded
Current or planned participation in a study of an investigational agent or using an investigational device
Currently receiving treatment in another investigational device or drug study, or less than 30 days between ending treatment on another investigational device or drug study(ies) and start of IP treatment. Other investigational procedures while participating in this study are excluded.
Investigational device within 4 weeks of the first dose of treatment
PHASE I AND PHASE II DOSE EXPANSION IN RECURRENT GBM UNDERGOING RESECTION: Is currently participating in a study of an investigational agent or using an investigational device for therapeutic purposes; concurrent use of Optune device is not allowed
Currently enrolled in another clinical study or used any investigational drug or device within 30 days (or 5 x half-life for investigational drugs where the half-life is known) preceding informed consent
Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s)
Currently receiving any investigational drug or device in another clinical trial or within 30 days preceding informed consent.
Use of any investigational product (IP) or investigational medical device within 28 days before day 1 of study drug
Subjects may not be receiving any other investigational agents; concurrent enrollment in another clinical investigational drug or device study is prohibited
Participation in an investigational drug or device study or treatment with any antineoplastic agent within 14 days of the first day of dosing on this study
Participation in an investigational drug or device study within 14 days of the first day of dosing on this study
Patient is simultaneously participating in another investigational drug or device study
Enrollment in any other investigational treatment study or use of an investigational agent, or has not yet completed at least 3 half-lives since ending another investigational device or drug trial
Patient is currently participating in a study with an investigational compound or device
Subjects who participated in an investigational drug or device study within 28 days prior to study entry
Received an investigational drug, was vaccinated with live attenuated vaccines, or used an invasive investigational medical device within 4 weeks before the planned first dose of study drug, or is currently being treated in an investigational study
Any other investigational agent or used an investigational device within 21 days prior to day 1 of protocol therapy
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 28 days prior to registration
Treatment with another investigational drug (with the exception of anticancer immune therapy) or device, or approved therapy for investigational use, within 5 times the half-life of the drug or within 3 weeks prior to study day 1 if the half life is not known.
Subject participating in any other study involving an investigational (unapproved) drug or device within the past 60 days.
Participated in any other study in which receipt of an investigational new drug or investigational device occurred within 28 days of first dose of study drug
Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study
Currently receiving treatment in another investigational device or drug study or less than 30 days since ending treatment on another investigational device or drug study. Other investigational procedures while participating in this study are excluded.
Are currently receiving treatment in a clinical trial involving an investigational product or non-approved use of a drug or device.
Concurrent use of another investigational drug or device therapy (ie, outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form).
Have discontinued investigational product or non approved use of a drug or device from a clinical trial within 30 days before the first day of study treatment.
Are currently enrolled in another clinical study or used any investigational drug or device within 30 days (or 5 x the half-life of the investigational drug/device, whichever is longer) preceding informed consent
Prior or concurrent exposure to any of the following: approved or investigational treatments for SMM or/and multiple myeloma, daratumumab or other anti CD-38 therapies, treatment with corticosteroids with a dose greater than (>) 10 milligram (mg) prednisone per day or equivalent and bone-protecting agents (eg, bisphosphonates, denosumab) or are only allowed if given in a stable dose and for a nonmalignant condition, or received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 4 weeks before Cycle 1, Day 1
Participation in any other investigational drug trial or exposure to other investigational agent, device or procedure within 30 days
Participant has received an investigational drug or used an invasive investigational medical device within 30 days prior to Study Entry or is currently enrolled in an investigational study
Concurrent use of another investigational drug or device (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)
Used an investigational device within 4 weeks of the first dose of treatment
The participant is currently enrolled in a clinical trial involving an investigational product or non-approved use of a drug or device.
Current or planned participation in a study of an investigational agent or using an investigational device
Patient has received an investigational agent or used an investigational device within 28 days of the first dose of study drug
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 21 days of trial entry (signing of the informed consent form)
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)
Current enrollment in an investigational drug or device study or participation in such a study within 4 weeks of cycle 1, day 1
Receipt of treatment with another investigational device or drug
Received ibrutinib or following therapies considered investigational for treatment of cGVHD including imatinib, bortezomib, ruxolitnib, or entospletinib, within 4 wks prior to starting AMG 592 or is currently receiving treatment in another investigational drug or device study.
Current enrollment in an investigational drug or device study or participation in such a study within 30 days of enrollment
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)
Patients who have not yet completed at least 21 days (30 days for prior monoclonal antibody therapy) since ending other investigational device or drug trials, or who are currently receiving other investigational treatments
Currently participating or enrolled in another investigational treatment, device or drug study through follow up
Subjects who participated in any other investigational drug trial or had exposure to any other investigational agent, device or procedure <4 weeks prior to Screening and throughout the entire trial, with the exception of investigational drugs administered prophylactically for CMV post allogeneic HCT.
Participation in a clinical trial of an investigational device or drug within 4 weeks of study entry.
Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or investigational drug study(s), or subject is receiving other investigational agent(s)
Participant has participated in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
Concurrent use of another investigational drug or device during, or within 3 weeks of starting study treatment
Concurrent use of another investigational drug or device during, or within 3 weeks of starting study treatment
Participation in any other investigational trial in which receipt of investigational drug or device occurred within 30 days prior to screening for this study
Current enrollment in another interventional clinical study or used any investigational drug or device within the past 28 days preceding informed consent.
Participant who were treated with other investigational drug or medical device within 4 weeks prior to the planned first day of study drug dosing.
Prior participation in an investigational study (procedure or device) within 21 days of study day 1
Any other investigational drug/medical device within 3 weeks prior to the first dose
Participation in concurrent study of an investigational agent or device.
Participating in another investigational drug or device trial that has not completed the follow-up period
Participant has been exposed to an investigational product (IP) or investigational device in another clinical study within 4 weeks prior to IP administration, or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
Treatment with another investigational drug or device within 28 days prior to Day 1
Currently enrolled in another investigational device or drug study
Use of investigational drug within 4 weeks of Day 1 Week 1 or current enrollment in an investigational drug or device study
Subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s) or subject is receiving other investigational agents.
Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s), or subject is receiving other investigational agent(s)
Patients who have received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 14 days or 5 half -lives before registration or is currently enrolled in the treatment stage of an investigational study are not eligible; please contact PI for further details on wash-out period and eligibility of such patients
Participating in any other investigational study for either drug or device which could influence collection of valid data under this study
Patients who have received an investigational agent or have used an investigational device within 4 weeks of the first dose of study drug
Currently enrolled in another interventional clinical study or used any investigational drug or device within the past 28 days preceding informed consent
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)
Prior treatment with any investigational drug or device within 30 days prior to Randomization (within 2 weeks for investigational or approved immunotherapy) or currently participating in other investigational procedures;
Subject has participated in an investigational drug or device research study within 30 days of enrollment that would interfere with this study.
Participating in another investigational drug or device study in which patient has not completed the follow-up phase for the primary endpoint at least 30 days prior to enrollment
Use of an investigational drug in the 3 months prior to screening and must agree to not participate in any drug or device study while enrolled in this study
Participation in any study with an investigational compound or device within 30 days prior to signing informed consent
Has participated in a study with an unapproved investigational compound (monoclonal antibodies are excepted) or device within 28 days of the first dose of study drug
Patient has been treated with an investigational drug, investigational biologic, or investigational therapeutic device within 14 days prior to study radiotracer administration
Patient has participated in a clinical study of an investigational drug or device within 3 months prior to screening CDU that may have an impact on clinical outcomes; and,
Treatment with any investigational drug, device or biologic agent within 30 days prior to administration of [18F]-ML-10.
Current enrollment in an investigational drug or device study, or participation in such a study within 30 days of first administration of the hormonal agent
Patient is participating in a clinical trial of another investigational drug or device
Planned participation in another study of an investigational agent or investigational device or use of a therapeutic device intended for therapy of glioma
Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study.
Patient is participating in any other investigational drug or device study
Patient is participating in a clinical trial of another investigational drug or device
Receipt of an investigational drug or device within 30 days of enrollment.
Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
